{"id":11658,"date":"2019-02-12T14:44:11","date_gmt":"2019-02-12T14:44:11","guid":{"rendered":"https:\/\/iach2019.cme-congresses.com\/?page_id=11658"},"modified":"2019-09-18T20:12:05","modified_gmt":"2019-09-18T20:12:05","slug":"program","status":"publish","type":"page","link":"https:\/\/iach2019.cme-congresses.com\/program\/","title":{"rendered":"Scientific Program"},"content":{"rendered":"

\n\t\t\t\t\t
\n\t\t\t\t\t\t

Scientific Program<\/h2><\/div>
<\/div>\n\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div><\/div><\/div>
\n\t\t\t\t\t
\n\t\t\t\t\t\t

Thursday, September 19, 2019<\/h3><\/div>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
<\/td>\nHall A<\/strong><\/td>\n<\/tr>\n
13:30-15:40<\/strong><\/td>\nHematology hot news session: advances in disease biology
\n<\/span><\/strong>Chairs: Irene Ghobria<\/strong>l, USA; Arnon Nagler<\/strong>, Israel<\/span>
\n<\/strong><\/td>\n<\/tr>\n
13:30-14:00<\/td>\nIntroduction to IACH activities and projects
\nMohamad Mohty<\/strong>, France; Arnon Nagler<\/strong>, Israel<\/td>\n<\/tr>\n
14:00-14:20<\/td>\nWaldenstrom macroglobulinemia
\nIrene Ghobrial<\/strong>, USA<\/td>\n<\/tr>\n
14:20-14:40<\/td>\nNew insights in NPM1-1 mutated AML
\nBrunangelo Falini<\/strong>, Italy<\/td>\n<\/tr>\n
14:40-15:00<\/td>\nMyelodysplastic syndromes
\nGhulam Mufti<\/strong>, UK<\/td>\n<\/tr>\n
15:00-15:20<\/td>\nMultiple myeloma
\nRobert Orlowski<\/strong>, USA<\/td>\n<\/tr>\n
15:20-15:40<\/td>\nITP
\nJenny Despotovic<\/strong>, USA<\/td>\n<\/tr>\n
15:40-16:00<\/strong><\/td>\nCoffee Break<\/em><\/td>\n<\/tr>\n
16:00-17:30<\/strong><\/td>\nPlenary Session 1: Advances in hematology
\n<\/span><\/strong>Chairs: Mohamad Mohty<\/strong>, France; He Huang<\/strong>, China<\/span>
\n<\/strong><\/td>\n<\/tr>\n
16:00-16:20<\/td>\nCurrent recommendation for TKI cessation in chronic myeloid leukemia (CML)
\nFrancois Guilhot<\/strong>, France<\/td>\n<\/tr>\n
16:20-16:40<\/td>\nCAR T cells: experience from China
\nHe Huang<\/strong>, China<\/td>\n<\/tr>\n
16:40-17:00<\/td>\nNext generation CAR T cells
\nSaad<\/strong> Kenderian<\/strong>, USA<\/td>\n<\/tr>\n
17:00-17:30<\/td>\nChronic lymphocytic leukemia: state-of-the-art therapy
\nGianluca Gaidano<\/strong>, Italy<\/td>\n<\/tr>\n
17:30-17:45<\/strong><\/td>\nShort Break<\/em><\/td>\n<\/tr>\n
17:45-18:30<\/strong><\/td>\nOpening Session: Keynote opening lecture and award presentation
\n<\/span><\/strong>Chairs: Mohamad Mohty<\/strong>, France; Arnon Nagler<\/strong>, Israel<\/span>
\n<\/strong><\/td>\n<\/tr>\n
17:45-18:00<\/td>\nPresentation of the H.J. Khoury excellence in research award<\/strong>
\n<\/strong><\/td>\n<\/tr>\n
18:00-18:30<\/td>\nManagement of elderly myeloma: 30 years of active research
\nThierry Facon<\/strong>, France<\/td>\n<\/tr>\n
18:30-19:30<\/strong><\/td>\nWelcome Reception<\/strong><\/em><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
<\/div>\n\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div><\/div><\/div>
\n\t\t\t\t\t
\n\t\t\t\t\t\t

Friday, September 20, 2019<\/h3><\/div>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
<\/td>\nHall A<\/strong><\/td>\n<\/td>\nHall B
\n<\/strong><\/td>\n<\/tr>\n
09:00-10:30<\/strong><\/td>\nSession F1A: Multiple myeloma
\n<\/span><\/strong>Chairs: Thierry Facon<\/strong>, France; Meral Beksa\u00e7<\/strong>, Turkey
\n<\/strong><\/td>\n		09:00-10:30<\/strong><\/td>\nSession F1B: Allogeneic stem cell transplant indications and results
\n<\/span><\/strong>Chairs: Ibrahim Yakoub-Agha<\/strong>, France; Jordi Sierra<\/strong>, Spain
\n<\/strong><\/td>\n<\/tr>\n
09:00-09:20<\/td>\nManagement of elderly myeloma
\nThierry Facon<\/strong>, France<\/td>\n		09:00-09:20<\/td>\nAcute lymphoblastic leukemia
\nSebastian Giebel<\/strong>, Poland<\/td>\n<\/tr>\n
09:20-09:40<\/td>\nManagement of transplant-eligible myeloma
\nMohamad Mohty<\/strong>, France<\/td>\n		09:20-09:40<\/td>\nAcute myeloid leukemia
\nArnon Nagler<\/strong>, Israel<\/td>\n<\/tr>\n
09:40-10:00<\/td>\nManagement of extra-medullary and high-risk myeloma
\nArtur Jurczyszyn<\/strong>, Poland<\/td>\n		09:40-10:00<\/td>\nMyelodysplastic syndromes
\nIbrahim Yakoub-Agha<\/strong>, France<\/td>\n<\/tr>\n
10:00-10:20<\/td>\nRelapsed myeloma
\nMeral Beksa\u00e7<\/strong>, Turkey<\/td>\n		10:00-10:20<\/td>\nMyeloproliferative neoplasms
\nNaveen Pemmaraju<\/strong>, USA<\/td>\n<\/tr>\n
10:20-10:30<\/td>\nDiscussion<\/td>\n10:20-10:30<\/td>\nDiscussion<\/td>\n<\/tr>\n
10:30-10:45<\/strong><\/td>\nShort Break<\/em><\/td>\n<\/tr>\n
10:45-12:15<\/strong><\/td>\nDriving a change in outcomes for high-risk AML* and hepatic veno-occlusive disease<\/strong><\/span><\/a>
\n*High-risk AML defined as therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC)<\/span>
\nIndustry-supported Lunch Symposium (Hall A)<\/strong><\/em><\/td>\n<\/tr>\n
12:15-12:45<\/strong><\/td>\nLunch Break<\/em><\/td>\n<\/tr>\n
12:45-14:15<\/strong><\/td>\nSession F2A: Myeloid diseases \u2013 Non-transplant approaches
\n<\/span><\/strong>Chairs: Thomas Prebet<\/strong>, USA; Naveen Pemmaraju<\/strong>, USA
\n<\/strong><\/td>\n		12:45-14:15<\/strong><\/td>\nSession F2B: Long-term complications and supportive care
\n<\/span><\/strong>Chairs: Rafael Duarte<\/strong>, Spain; Didier Blaise<\/strong>, France
\n<\/strong><\/td>\n<\/tr>\n
12:45-13:05<\/td>\nAPL
\nMiguel A. Sanz<\/strong>, Spain<\/td>\n		12:45-13:05<\/td>\nManagement of CMV infections
\nRafael Duarte<\/strong>, Spain<\/td>\n<\/tr>\n
13:05-13:25<\/td>\nRisk stratification in AML
\nFran\u00e7ois Delhommeau<\/strong>, France<\/td>\n		13:05-13:25<\/td>\nLate events after reduced-intensity conditioning
\nAvichai Shimoni<\/strong>, Israel<\/td>\n<\/tr>\n
13:25-13:45<\/td>\nManagement of elderly AML
\nThomas Prebet<\/strong>, USA<\/td>\n		13:25-13:45<\/td>\nCoronary and artery disease
\nMinoo<\/strong> Battiwalla<\/strong>, USA<\/td>\n<\/tr>\n
13:45-14:05<\/td>\nManagement of young AML (outside transplant)
\nJordi Sierra<\/strong>, Spain<\/td>\n		13:45-14:05<\/td>\nLong-term complications after HCT
\nMinoo<\/strong> Battiwalla<\/strong>, USA<\/td>\n<\/tr>\n
14:05-14:15<\/td>\nDiscussion<\/td>\n14:05-14:15<\/td>\nDiscussion<\/td>\n<\/tr>\n
14:15-14:45<\/strong><\/td>\nBreak, Poster Viewing and Visit Exhibition<\/em><\/td>\n<\/tr>\n
14:45-16:15<\/strong><\/td>\nSession F3A: Non-Hodgkin lymphoma
\n<\/span><\/strong>Chairs: Mohamed Kharfan-Dabaja<\/strong>, USA; Ali Bazarbachi<\/strong>, Lebanon
\n<\/strong><\/td>\n		14:45-16:15<\/strong><\/td>\nSession F3B: Allogeneic stem cell transplant complications
\n<\/span><\/strong>Chairs: Gonzalo Guti\u00e9rrez Garc\u00eda<\/strong>, Spain; Mutlu Arat<\/strong>, Turkey
\n<\/strong><\/td>\n<\/tr>\n
14:45-15:05<\/td>\nMantle cell lymphoma
\nOlivier Hermine<\/strong>, France<\/td>\n		14:45-15:05<\/td>\nEndothelium-related complications
\nGonzalo Guti\u00e9rrez Garc\u00eda<\/strong>, Spain<\/td>\n<\/tr>\n
15:05-15:25<\/td>\nHigh-grade lymphoma
\nChristian Gisselbrecht<\/strong>, France<\/td>\n		15:05-15:25<\/td>\nHow I prevent GVHD
\nSamer Al-Homsi<\/strong>, USA<\/td>\n<\/tr>\n
15:25-15:45<\/td>\nIndolent lymphoma
\nOlivier Hermine<\/strong>, France<\/td>\n		15:25-15:45<\/td>\nTherapy of acute GVHD
\nErnst Holler<\/strong>, Germany<\/td>\n<\/tr>\n
15:45-16:05<\/td>\nChronic lymphocytic leukemia
\nMohamed Kharfan-Dabaja<\/strong>, USA<\/td>\n		15:45-16:05<\/td>\nChallenges in chronic GVHD clinical trials
\nIskra Pusic<\/strong>, USA<\/td>\n<\/tr>\n
16:05-16:15<\/td>\nDiscussion<\/td>\n16:05-16:15<\/td>\nDiscussion<\/td>\n<\/tr>\n
16:15-16:30<\/strong><\/td>\nCoffee Break, Poster Viewing and Visit Exhibition<\/em><\/td>\n<\/tr>\n
16:30-18:00<\/strong><\/td>\nSession F4A: Acute lymphoblastic leukemia (ALL)
\n<\/span><\/strong>Chairs: Hagop Kantarjian<\/strong>, USA; Sebastian Giebel<\/strong>, Poland
\n<\/strong><\/td>\n		16:30-18:00<\/strong><\/td>\nSession F4B: Advances in allogeneic stem cell transplantation
\n<\/span><\/strong>Chairs: Didier Blaise<\/strong>, France; Avichai Shimoni<\/strong>, Israel
\n<\/strong><\/td>\n<\/tr>\n
16:30-16:50<\/td>\nCAR T cells in ALL
\nJordan Gauthier<\/strong>, USA<\/td>\n		16:30-16:50<\/td>\nHaplo-identical versus unrelated and mismatched donors
\nGiorgia Battipaglia<\/strong>, France<\/td>\n<\/tr>\n
16:50-17:10<\/td>\nNovel antibodies in relapsed\/refractory ALL
\nEolia Brissot<\/strong>, France<\/td>\n		16:50-17:10<\/td>\nConditioning for haplo-identical transplantation
\nDidier Blaise<\/strong>, France<\/td>\n<\/tr>\n
17:10-17:30<\/td>\nWhich intensity of therapy is required in ALL?
\nDieter Hoelzer<\/strong>, Germany<\/td>\n		17:10-17:30<\/td>\nRole of the microbiota
\nFlorent Malard<\/strong>, France<\/td>\n<\/tr>\n
17:30-17:50<\/td>\nManagement of elderly ALL
\nHagop Kantarjian<\/strong>, USA<\/td>\n		17:30-17:50<\/td>\nEx-vivo expansion for cord blood transplantation
\nAnnalisa Ruggeri<\/strong>, France<\/td>\n<\/tr>\n
17:50-18:00<\/td>\nDiscussion<\/td>\n17:50-18:00<\/td>\nDiscussion<\/td>\n<\/tr>\n
18:00-19:00<\/strong><\/td>\nSession F5A: MRD in hematologic malignancies
\n<\/span><\/strong>Chairs: Christopher Hourigan<\/strong>, USA; Eolia Brissot<\/strong>, France
\n<\/strong><\/td>\n		18:00-19:00<\/strong><\/td>\nSession F5B: Case report forum
\n<\/span><\/strong>Chairs: Mohamad Mohty<\/strong>, France; Michael Byrne<\/strong>, USA
\n<\/span><\/strong><\/td>\n<\/tr>\n
18:00-18:20<\/td>\nCurrent status in CLL
\nIlaria Del<\/strong> Giudice<\/strong>, Italy<\/td>\n		18:00-18:20<\/td>\nHow to write a good paper
\nJunia Melo<\/strong>, Australia<\/td>\n<\/tr>\n
18:20-18:40<\/td>\nCurrent status in AML
\nChristopher Hourigan<\/strong>, USA<\/td>\n		18:20-18:40<\/td>\nA complex transplant case (1)
\nJean El-Cheikh<\/strong>, Lebanon<\/td>\n<\/tr>\n
18:40-19:00<\/td>\nCurrent status in ALL
\nEolia Brissot<\/strong>, France<\/td>\n		18:30-18:40<\/td>\nA complex transplant case (2)
\nBhagirathbhai Dholaria<\/strong>, USA<\/td>\n<\/tr>\n
<\/td>\n<\/td>\n18:40-18:50<\/td>\nBarriers to clinical trial enrollment in HSCT
\nMichael Byrne<\/strong>, USA
\n<\/em><\/td>\n<\/tr>\n
<\/td>\n<\/td>\n18:50-19:00<\/td>\nDiscussion<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
<\/div>\n\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div><\/div><\/div>
\n\t\t\t\t\t
\n\t\t\t\t\t\t

Saturday, September 21, 2019<\/h3><\/div>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
<\/td>\nHall A<\/strong><\/td>\n<\/td>\nHall B
\n<\/strong><\/td>\n<\/tr>\n
08:00-09:00<\/strong><\/td>\nSession S1A: Transfusion medicine and haemostasis
\n<\/span><\/strong>Chairs: James Bussel<\/strong>, USA; Stephane Giraudier<\/strong>, France
\n<\/strong><\/td>\n		08:00-09:00<\/strong><\/td>\nSession S1B: Red blood cell disorders
\n<\/span><\/strong>Chair: Pierre Brissot<\/strong>, France
\n<\/strong><\/td>\n<\/tr>\n
08:00-08:30<\/td>\nMassive bleeding \u2013 which recipe?
\nPierre Pasquier<\/strong>, France<\/td>\n		08:00-08:20<\/td>\nIron deficiency anemia
\nMaria Domenica Cappellini<\/strong>, Italy<\/td>\n<\/tr>\n
08:30-09:00<\/td>\nDiagnosis of ITP
\nJames Bussel<\/strong>, USA<\/td>\n		08:20-08:40<\/td>\nThalassemia
\nMaria Domenica Cappellini<\/strong>, Italy<\/td>\n<\/tr>\n
<\/td>\n<\/td>\n08:40-09:00<\/td>\nSickle cell disease
\nSelim Corbacioglu<\/strong>, Germany<\/td>\n<\/tr>\n
09:00-10:00<\/strong><\/td>\nSession S2A: Platelet disorders
\n<\/span><\/strong>Chairs: James Bussel<\/strong>, USA; Stephane Giraudier<\/strong>, France
\n<\/strong><\/td>\n		09:00-10:00<\/strong><\/td>\nSession S2B: Iron-related disorders
\n<\/span><\/strong>Chair: Pierre Brissot<\/strong>, France
\n<\/strong><\/td>\n<\/tr>\n
09:00-09:30<\/td>\nManagement of ET
\nStephane Giraudier<\/strong>, France<\/td>\n		09:00-09:20<\/td>\nHepcidin, the “iron hormone”: update on its regulation
\nLaura Silvestri<\/strong>, Italy<\/td>\n<\/tr>\n
09:30-10:00<\/td>\nSecondary ITP: the game changers
\nJames Bussel<\/strong>, USA<\/td>\n		09:20-09:40<\/td>\nHereditary aceruloplasminemia
\nOlivier Lor\u00e9al<\/strong>, France<\/td>\n<\/tr>\n
<\/td>\n<\/td>\n09:40-10:00<\/td>\nPlasma transferrin saturation: revisiting its importance and interpretation
\nPierre Brissot<\/strong>, France<\/td>\n<\/tr>\n
10:00-10:30<\/strong><\/td>\nCoffee Break, Poster Viewing and Visit Exhibition<\/em><\/td>\n<\/tr>\n
10:30-11:30<\/strong><\/td>\nSession S3A: Management of aplastic anemia, MDS and sAML
\n<\/span><\/strong>Chairs: Thomas Cluzeau<\/strong>, France; Elena Solomou<\/strong>, Greece
\n<\/strong><\/td>\n		10:30-11:30<\/strong><\/td>\nSession S3B: Toxicities in HSCT
\n<\/span><\/strong>Chairs: Navneet Majhail<\/strong>, USA; Brian Engelhardt,<\/strong> USA
\n<\/strong><\/td>\n<\/tr>\n
10:30-10:50<\/td>\nAplastic anemia
\nCarlos Vallejo<\/strong>, Spain<\/td>\n		10:30-10:50<\/td>\nIron toxicity
\nEmanuele Angelucci<\/strong>, Italy<\/td>\n<\/tr>\n
10:50-11:10<\/td>\nLow risk MDS
\nThomas Cluzeau<\/strong>, France<\/td>\n		10:50-11:10<\/td>\nCardiac toxicity
\nR\u00e9my Dul\u00e9ry<\/strong>, France<\/td>\n<\/tr>\n
11:10-11:30<\/td>\nSecondary AML
\nYngvar Fl\u00f8isand<\/strong>, Norway<\/td>\n		11:10-11:30<\/td>\nPsychosocial complications
\nNavneet Majhail<\/strong>, USA<\/td>\n<\/tr>\n
11:30-11:45<\/strong><\/td>\nShort Break<\/em><\/td>\n<\/tr>\n
11:45-12:45<\/strong><\/td>\nCAR T cells in lymphoid malignancies: current status and perspectives<\/span><\/a>
\nNon-profit Lunch Symposium (Hall A)<\/strong><\/em>
\n<\/strong><\/td>\n<\/tr>\n
12:45-13:15<\/strong><\/td>\nLunch Break<\/em><\/td>\n<\/tr>\n
13:15-14:15<\/strong><\/td>\nSession S4A: Management of Hodgkin lymphoma and rare T cell NHLs
\n<\/span><\/strong>Chairs: Ali Bazarbachi<\/strong>, Lebanon; Owen A. O\u2019Connor<\/strong>, USA
\n<\/strong><\/td>\n		13:15-14:15<\/strong><\/td>\nSession S4B: Immunology of HSCT \u2013 Clinical implications
\n<\/span><\/strong>Chairs: R\u00e9my Dul\u00e9ry<\/strong>, France; Yngvar Fl\u00f8isand<\/strong>, Norway
\n<\/strong><\/td>\n<\/tr>\n
13:15-13:35<\/td>\nT cell NHL
\nOwen A. O’Connor<\/strong>, USA<\/td>\n		13:15-13:35<\/td>\nPost-Cy as a platform for GVHD prevention
\nLeonido Luznik<\/strong>, USA<\/td>\n<\/tr>\n
13:35-13:55<\/td>\nHow I manage relapsed Hodgkin lymphoma
\nAnas Younes<\/strong>, USA<\/td>\n		13:35-13:55<\/td>\nPredicting immunometabolic complications
\nBrian Engelhardt<\/strong>, USA
\n<\/em><\/td>\n<\/tr>\n
13:55-14:15<\/td>\nAllotransplant for relapsed Hodgkin lymphoma
\nAli Bazarbachi<\/strong>, Lebanon<\/td>\n		13:55-14:15<\/td>\nNovel approaches in the management of refractory chronic GVHD
\nZinaida Peri\u0107<\/strong>, Croatia<\/td>\n<\/tr>\n
14:15-14:45<\/strong><\/td>\nBreak, Poster Viewing and Visit Exhibition<\/em><\/td>\n<\/tr>\n
14:45-16:15<\/strong><\/td>\nSession S5A: Clinical experiences from around the world
\n<\/span><\/strong>Chair: Shinichiro Okamoto<\/strong>, Japan
\n<\/strong><\/td>\n		14:45-16:15<\/strong><\/td>\nSession S5B: Making the right diagnosis in hematology
\n<\/span><\/strong>Chairs: Elad Jacoby<\/strong>, Israel; Florent Malard<\/strong>, France
\n<\/strong><\/td>\n<\/tr>\n
14:45-15:00<\/td>\nOptimizing resources for bone marrow transplantation
\nGregorio Jaimovich<\/strong>, Argentina<\/td>\n		14:45-15:00<\/td>\nMastocytosis
\nGandhi Damaj<\/strong>, France<\/td>\n<\/tr>\n
15:00-15:15<\/td>\nEstablishment of National Donor Registry and impact on transplant kinetics and outcome: TURKOK experience 2015-2018
\nMutlu Arat<\/strong>, Turkey<\/td>\n		15:00-15:15<\/td>\nCRS after CAR T cells therapy
\nElad Jacoby<\/strong>, Israel<\/td>\n<\/tr>\n
15:15-15:30<\/td>\nLate complications after allogeneic stem cell transplantation
\nShinichiro Okamoto<\/strong>, Japan<\/td>\n		15:15-15:30<\/td>\nVenous thromboembolism: update on prevention and treatment
\nGrigorios Gerotziafas<\/strong>, France<\/td>\n<\/tr>\n
15:30-15:45<\/td>\nMultiple myeloma: relapse after autologous stem cell transplantation \u2013 incidence, pattern, risk factors and clinical significance
\nLalit Kumar<\/strong>, India<\/td>\n		15:30-15:45<\/td>\nLeucopenia
\nElena Solomou<\/strong>, Greece<\/td>\n<\/tr>\n
15:45-16:00<\/td>\nHigh-dose TEAM chemotherapy followed by autologous PBSCT in lymphoma
\nAhmad Ibrahim<\/strong>, Lebanon<\/td>\n		15:45-16:00<\/td>\nRole of artificial intelligence: machine learning in diagnostic hematology
\nShahrukh Hashmi<\/strong>, USA<\/td>\n<\/tr>\n
16:00-16:15<\/td>\nDiscussion<\/td>\n16:00-16:15<\/td>\nMachine learning-based algorithms
\nAziz<\/strong> Nazha<\/strong>, USA<\/td>\n<\/tr>\n
16:15-16:45<\/strong><\/td>\nCoffee Break, Poster Viewing and Visit Exhibition<\/em><\/td>\n<\/tr>\n
16:45-18:30<\/strong><\/td>\nPlenary Session 2: State-of-the-art management of …
\n<\/span><\/strong>Chairs: Jean-Luc Harousseau<\/strong>, France; Anas Younes<\/strong>, USA
\n<\/strong><\/td>\n<\/tr>\n
16:45-17:15<\/td>\n… acute lymphoblastic leukemia
\nHagop Kantarjian<\/strong>, USA<\/td>\n<\/tr>\n
17:15-17:45<\/td>\n… multiple myeloma
\nJean-Luc Harousseau<\/strong>, France<\/td>\n<\/tr>\n
17:45-18:15<\/td>\n… precision medicine and immunotherapy in non-Hodgkin lymphoma
\nAnas Younes<\/strong>, USA<\/td>\n<\/tr>\n
18:15-18:30<\/td>\nDiscussion<\/td>\n<\/tr>\n
18:30<\/strong><\/td>\nMeeting conclusions and closure
\nMohamad Mohty<\/strong>, France; Arnon Nagler<\/strong>, Israel<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
<\/div>\n\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div><\/div><\/div><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"100-width.php","meta":{"footnotes":""},"yst_prominent_words":[34,29,32,33,46,31,23,28,519,468,243,237,25,467,44,26,24,238,35,27],"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/iach2019.cme-congresses.com\/wp-json\/wp\/v2\/pages\/11658"}],"collection":[{"href":"https:\/\/iach2019.cme-congresses.com\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/iach2019.cme-congresses.com\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/iach2019.cme-congresses.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/iach2019.cme-congresses.com\/wp-json\/wp\/v2\/comments?post=11658"}],"version-history":[{"count":0,"href":"https:\/\/iach2019.cme-congresses.com\/wp-json\/wp\/v2\/pages\/11658\/revisions"}],"wp:attachment":[{"href":"https:\/\/iach2019.cme-congresses.com\/wp-json\/wp\/v2\/media?parent=11658"}],"wp:term":[{"taxonomy":"yst_prominent_words","embeddable":true,"href":"https:\/\/iach2019.cme-congresses.com\/wp-json\/wp\/v2\/yst_prominent_words?post=11658"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}